Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04938622
Other study ID # 990878
Secondary ID R01HD039245-01
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2001
Est. completion date April 30, 2005

Study information

Verified date June 2021
Source Penn State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Menstrual disturbances are frequently observed in physically active women and female athletes. Short term prospective studies have shown that diet and exercise interventions can lead to decreases in Luteinizing hormone (LH) pulsatility, however these studies are unable to capture further changes in menstrual status. One longer term prospective study over two menstrual cycles showed that weight loss elicited menstrual disturbances, but there were no quantifiable measurements of energy availability. Thus, the primary purpose of this study was to assess how varying levels of energy deficiency created through a combination of caloric restriction and exercise affect menstrual function in young, premenopausal, sedentary women.


Description:

Long term energy deficiency in women can lead to functional hypothalamic amenorrhea (FHA), which can cause many health detriments such as osteopenia, stress fractures, transient infertility, dyslipidemia, and impaired endothelial function. Though studies involving diet and exercise interventions have shown how energy deficiency can lead to menstrual disturbances prospectively, this study aims to extend those findings by measuring the magnitude of energy deficit that could lead to these disturbances. Hypotheses for this study are: 1) there would be a dose-response relation between the induction of menstrual disturbances (luteal phase defects, anovulation, and oligomenorrhea) and the magnitude of energy deficiency such that the intervention groups experiencing a greater energy deficit would incur a significantly greater incidence of menstrual cycle disturbances and 2) the intervention groups experiencing a greater energy deficit would incur a greater incidence of more severe menstrual cycle disturbances. The study included one baseline menstrual cycle and 3 intervention menstrual cycles. During the baseline period, participants were randomly assigned to an experimental group for intervention menstrual cycles 1, 2, and 3 of the study. The goal of the subject groupings was to test the impact of varying levels of an energy deficit created by the combination of caloric restriction and exercise on menstrual function. They were assigned to either a control group that did not exercise and consumed a number of calories estimated to maintain body weight, a control group that exercised but received extra food calories to remain in energy balance (EXCON), or one of four groups that exercised and were prescribed reduced energy intake to create varying levels of an energy deficit. Specifically, the four groups of energy deficit were 1) an increase of 15 percent kcal of exercise (15 percent deficit, ED1), 2) an increase of 30 percent kcal of exercise (30 percent deficit, ED2), 3) a decrease of 15 percent in dietary intake combined with an increase of 15 percent of exercise, (30 percent deficit 15/15, ED2), and 4) a decrease of 30 percent in dietary intake combined with an increase of 30 percent kcal of exercise (60 percent deficit, ED3). The number of participants for analysis was 34 participants in the following groups: EXCON (n = 8), ED1 (n = 6), ED2 (n = 12), and ED3 (n = 8). Baseline energy needs were assessed during the baseline cycle. Resting metabolic rate and nonexercise physical activity were added to determine a caloric need for the day. Caloric intake was supervised throughout the entire study, and meals were comprised of 55 percent carbohydrates, 30 percent fat, and 15 percent protein. Exercise training was also supervised, and maximal oxygen consumption (VO2 max) was calculated. Menstrual status was assessed through analysis of daily urinary metabolites of estrone-1-glucuronide (E1G), pregnanediol glucuronide (PdG), and midcycle LH. Underwater weighing and a digital scale were used to assess body composition, and fasting blood samples were collected to assess metabolic hormones.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date April 30, 2005
Est. primary completion date April 30, 2005
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Weight 45-75 kg - Body fat 15-35 percent - BMI 18-25 kg/m2 - Nonsmoking - <1 hour/week of purposeful aerobic exercise for the past 6 months - Documentation of at least two ovulatory menstrual cycles during screening. Exclusion Criteria: - History of serious medical conditions - Medication use that would alter metabolic hormone levels - Significant weight loss/gain (±2.3 kg) in the last year - Current evidence of disordered eating or history of an eating disorder - Taking exogenous hormonal contraceptives for the past 6 months

Study Design


Intervention

Other:
Sedentary Control
Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
Exercising control
Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
15 percent energy deficit
Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs. Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
30 percent energy deficit
Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs. Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
30 percent energy deficit (15/15)
Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs. Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
60 percent energy deficit
Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs. Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Penn State University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)

References & Publications (2)

Lieberman JL, DE Souza MJ, Wagstaff DA, Williams NI. Menstrual Disruption with Exercise Is Not Linked to an Energy Availability Threshold. Med Sci Sports Exerc. 2018 Mar;50(3):551-561. doi: 10.1249/MSS.0000000000001451. — View Citation

Williams NI, Leidy HJ, Hill BR, Lieberman JL, Legro RS, De Souza MJ. Magnitude of daily energy deficit predicts frequency but not severity of menstrual disturbances associated with exercise and caloric restriction. Am J Physiol Endocrinol Metab. 2015 Jan — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in frequency of menstrual disturbances (disturbances /cycle) Frequency of menstrual disturbances including luteal phase defects, anovulation, oligomenorrhea cycles, and anovulatory cycles analyzed by daily urinary metabolites of estrone-1-glucuronide (E1G), pregnanediol glucuronide (PdG), and midcycle LH Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC)
Secondary Change in percent body fat Change in percent body fat (%) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC), & Post Study (days 1-7)
Secondary Change in metabolic hormones Change in metabolic hormones total triiodothyronine (T3 ng/dL)) and insulin-like growth factor-1 (IGF-1 ng/ml). Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, Mid- study (week 3 of MC during intervention MC 2) an (28 days (d) or the length of 1 MC), & Post Study (Days (d)1-7 of cycle
Secondary Change in cycle length (days (d)) Change in cycle length (days (d)) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC)
Secondary Change in aerobic capacity Change in aerobic capacity, VO2 max (ml/kg/min) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, & Post Study (Days (d)1-7 of cycle
Secondary Change in body weight Body weight (kg) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC), & Post Study (days 1-7)
Secondary Change in fat mass Change in fat mass (kg) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC), & Post Study (days 1-7)
Secondary Change in fat free mass Change in fat free mass (kg) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC), & Post Study (days 1-7)
Secondary Change in follicular phase length Change in follicular phase length (days (d)) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC)
Secondary Change in luteal phase length Change in luteal phase length (days (d)) Baseline Menstrual Cycle (MC) (28 days (d) or the length of 1 MC, intervention MC 1 (28 days or the length of 1 MC), intervention MC 2 (28 days or the length of 1 MC), and intervention MC 3 (28 days or the length of 1 MC)
See also
  Status Clinical Trial Phase
Completed NCT01927432 - Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea
Completed NCT00196391 - A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea Phase 2
Completed NCT00152282 - A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women Phase 2
Recruiting NCT00456274 - Baselines in Reproductive Disorders N/A
Terminated NCT00556400 - Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones Phase 1/Phase 2
Completed NCT00429494 - GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Phase 2
Completed NCT04135729 - Mental Health in Fitness Instructors
Recruiting NCT03916978 - Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women Phase 2/Phase 3
Completed NCT00243607 - Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors N/A
Completed NCT00001275 - Ovarian Follicle Function in Patients With Primary Ovarian Failure N/A
Recruiting NCT06280807 - Observation of Environment and Reproductive-Endocrine Effects
Not yet recruiting NCT02393482 - Psychological Impact of Amenorrhea in Women With Endometriosis Phase 4
Completed NCT01206153 - Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients Phase 4
Recruiting NCT04424576 - Ovarian Morphology in Girls
Completed NCT02224976 - Effect of Intense Training on Ovarian Function and Bone Turnover N/A
Active, not recruiting NCT01785719 - Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss N/A
Recruiting NCT00383656 - Pulsatile GnRH in Anovulatory Infertility Phase 2
Terminated NCT00881608 - Study to Evaluate Menses Induction in Women Administered Proellex Phase 1
Active, not recruiting NCT01103518 - Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Phase 4
Withdrawn NCT00827151 - Bone Mass Accrual in Adolescent Athletes Phase 3